Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906620 | 0.89 | FAAH (0.45) | DRD2CCR8FAAH | |
| SCHEMBL9906612 | 0.85 | DRD2 (0.46) | DRD2CCR8FAAHLMNA | |
| SCHEMBL3117108 | 0.84 | PPARG (0.47) | CCR8FAAHLMNA | |
| SCHEMBL9906636 | 0.83 | SPHK1 (0.47) | CXCR4DRD2 | |
| SCHEMBL9906617 | 0.83 | DRD2 (0.41) | DRD2CCR8FAAHLMNA | |
| SCHEMBL9906594 | 0.82 | FAAH (0.45) | CCR8FAAH | |
| SCHEMBL9906615 | 0.79 | RAB9A (0.57) | CXCR4LMNA | |
| Trifluoroacetic Acid SCHEMBL3116154 | 0.79 | PPARG (0.46) | CCR8FAAHLMNA | |
| SCHEMBL9906610 | 0.78 | DRD2 (0.46) | DRD2CCR8FAAH | |
| SCHEMBL13540691 | 0.73 | ALDH1A1 (0.47) | CXCR4DRD2CCR8FAAHLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198303-B2 | Methods of use and compositions for the diagnosis and treatment of infectious diseases | SEQUELLA, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | SEQUELLA, INC. | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273826-A1 | METHODS OF USE AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES | C5, THPO, TERT | CXCR4 2123/4885DRD2 3352/4885CCR8 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.